Mr. Donald McCaffrey reports

PUBLICATIONS CONFIRM RVX-208 IS A UNIQUE SELECTIVE BET BROMODOMAIN ANTAGONIST

A publication titled "RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist" was published on Dec. 31, 2013, in the international, peer-reviewed, open-access on-line publication PLOS ONE journal. The publication was authored by Resverlogix Corp. staff in combination with collaborators from Xtal Biostructures Inc. in Maryland, United States.

This publication is the third recent publication discussing the unique attributes of RVX-208. In October, 2013, the Structural Genomics Consortium, in conjunction with a group of University of Oxford (United Kingdom) scientists, published a work titled "RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain." This paper was a peer-reviewed publication in by the Proceedings of the National Academy of Sciences of the United States of America.

"The Structural Genome (Oxford) paper was viewed by us as an extremely important publication as it confirmed by an external group for the first time that RVX-208 was the first known selective BET inhibitor, thus highlighting Resverlogix's technological lead in the bromodomain space," said Donald J. McCaffrey, president and chief executive officer of Resverlogix.

In August, 2013, a third publication in the Cell Journal, titled "BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure," used RVX-208 as one of the BET inhibitors that confirmed the potential for BET inhibitors as therapeutic targets in heart failure. The authors of this publication were primarily from various divisions of Harvard Medical School.

We seek Safe Harbor.